Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

Accrued Expenses

6 Months Ended

Jun. 30, 2023

Accrued Expenses

Accrued Expenses

5Accrued Expenses

Accrued expenses consist of the following:


		June 30,			December 31,
		2023			2022
Accrued interest on preferred members’ interests		$	188,085		$	188,085
Accrued compensation			62,735			159,704
Accrued professional fees			41,950			11,600
Accrued clinical research costs			7,807			78,349
Accrued director fees			—			31,000
Other miscellaneous accrued expenses			5,150			1,360
		$	305,727		$	470,098